In this regard, mastermind-like 1 (MAML1), a molecule with few side effects, may be used for targeting CD44+ CSCs via repressing the canonical NOTCH pathway in esophageal squamous cell carcinoma (ESCC) patients (Moghbeli et al., 2019). This evidence concerns the gene MAML1 and esophageal squamous cell carcinoma.